ALSO NOTED: FDA: New Zyprexa sedates some;Vanderbilt outlaws rep freebies;

> Prepping for advisory panel review, FDA staff says long-lasting Zyprexa causes drowsiness. Report

> Vanderbilt Medical Center has become the latest hospital to ban gifts from drug reps as part of a new conflict-of-interest policy. Report

> European regulators gave the nod to Roche's chemotherapy drug Xeloda for use against metastatic colorectal cancer in combo with other chemo meds. Report

> U.K. doctors called on the National Health Service to share more information about its dealings with the pharmaceutical industry. Report

> Bayer CEO Werner Wenning says the company has plenty of cash to make acquisitions even after last year's buyout of German drug maker Schering. Report

> Schering-Plough got the FDA nod for its Asmanex Twisthaler asthma treatment for prevention of symptoms in children 4 to 11 years. Report

> Three more congressmen have joined the fray over Denderon's delayed prostate cancer vaccine Provenge. Report

> Following a label change, Novartis has won EU approval for its trouble diabetes drug Galvus. Report

> Biotech and emerging drug markets are big targets for venture capitalists. Report

And Finally... Could low-salt and high-veggie diets succeed where blood pressure meds fail? Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.